Freestone Grove Partners’s Nu Skin NUS Stock Holding History

Freestone Grove Partners’s Portfolio NUS Stock Details NUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-43,337	Closed	-$299K	–	730
2024 Q4	$299K	Buy	+43,337	New	+$298K	﹤0.01%	469

Other funds holding NUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Freestone Grove Partners's NUS Position: Q1 2025 in Review

Freestone Grove Partners sold out of Nu Skin (NUS) in Q1 2025, closing a stake of 43,337 shares — an estimated $299K sold.

Freestone Grove Partners first reported a position in NUS in Q4 2024 and held it in 1 quarter. The position peaked at $299K in Q4 2024. 195 funds tracked by Wall St. Rank hold NUS as of Q1 2025.

Freestone Grove Partners reported no remaining Nu Skin position as of Q1 2025 after selling out during the quarter.
Freestone Grove Partners sold 43,337 Nu Skin shares in Q1 2025, an estimated $299K.
Freestone Grove Partners first reported a position in Nu Skin in Q4 2024 and held it in 1 quarter.
Freestone Grove Partners's Nu Skin position peaked at $299K in Q4 2024.
195 funds tracked by Wall St. Rank held Nu Skin as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.